News
CUE
0.9300
-1.08%
-0.0102
Weekly Report: what happened at CUE last week (0708-0712)?
Weekly Report · 10h ago
Weekly Report: what happened at CUE last week (0701-0705)?
Weekly Report · 07/08 10:55
Weekly Report: what happened at CUE last week (0624-0628)?
Weekly Report · 07/01 10:56
Weekly Report: what happened at CUE last week (0617-0621)?
Weekly Report · 06/24 11:02
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
NASDAQ · 06/21 11:54
Weekly Report: what happened at CUE last week (0610-0614)?
Weekly Report · 06/17 10:54
Weekly Report: what happened at CUE last week (0603-0607)?
Weekly Report · 06/10 10:56
Cue Biopharma Welcomes Michael J. Fox to Board, Shareholders Vote
TipRanks · 06/07 21:10
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Pharvaris (PHVS) and Cue Biopharma (CUE)
3 analysts just weighed in on OrthoPediatrics, Pharvaris and Cue Biopharma with bullish sentiments. In a report released today, JMP Securities reiterated a Buy rating on the Healthcare sector stocks. The analysts also reiterated their bullish sentiments on the company’s shares.
TipRanks · 06/06 05:31
CUE BIOPHARMA PRESENTS UPDATED DATA FROM PHASE 1 TRIAL OF CUE-101 IN RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER AT THE 2024 ASCO ANNUAL MEETING
Reuters · 06/04 12:00
Weekly Report: what happened at CUE last week (0527-0531)?
Weekly Report · 06/03 10:59
Weekly Report: what happened at CUE last week (0520-0524)?
Weekly Report · 05/27 11:03
Weekly Report: what happened at CUE last week (0513-0517)?
Weekly Report · 05/20 10:57
Cue Biopharma’s Promising Future: A Comprehensive Buy Rating Justification
TipRanks · 05/16 04:25
Weekly Report: what happened at CUE last week (0506-0510)?
Weekly Report · 05/13 11:05
Cue Biopharma, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/10 11:58
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
TipRanks · 05/10 11:57
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
Cue Biopharma reported results for the first quarter of 2024. The company reported earnings per share of -25 cents and revenue of $1.72 million. This was 41.90% better than the analyst estimate of -28 cents. Cue Biopharm reported earnings for the quarter was better than expected.
Investorplace · 05/10 03:54
Cue Biopharma Inc reports results for the quarter ended in January - Earnings Summary
Cue Biopharma Inc reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 25 cents per share. Revenue rose 818.2% to $1.72 million from a year ago. The average analyst rating on the shares is "strong buy"
Reuters · 05/09 22:04
Cue Biopharma GAAP EPS of -$0.25 beats by $0.03, revenue of $1.7M beats by $0.49M
Earnings News Cue Biopharma GAAP EPS of -$0.25 beats by $0.03, revenue of $1.7M beats by £794.7% in Q1. As of March 31, 2024, the company had $41M in cash and cash equivalents.
Seeking Alpha · 05/09 22:04
More
Webull provides a variety of real-time CUE stock news. You can receive the latest news about Cue Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.